Report: Authorized generic versions of Lipitor capture 14.6% of script volume
NEW YORK — Though they’ve been on the market for less than a month, the generic and authorized generic versions of Pfizer’s cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.
Citing an analysis of data from IMS Health by J.P. Morgan, The Wall Street Journal reported that Ranbaxy’s generic atorvastatin calcium tablets and Watson Pharmaceuticals’ authorized generic have claimed about 14.6% of prescription volume since their launch on Nov. 30.
Ranbaxy and Watson respectively launched their generic and authorized generic versions of Lipitor the day Pfizer lost its patent protection for the drug, which IMS estimated to have sales of $7.8 billion during the latest moving-annual period. An authorized generic is a branded drug launched under its generic name at a reduced price, usually under a contract between the original branded drug’s manufacturer and a third-party company.
I am a retired pharmacist. I went to get my Lipitor refilled and found out the Brand Name Lipitor and the new generic version was to cost me the exact same price. This was through Community Rx Part D, I am in the doughnut hole, so I just decided to wait until January and get the Rx filled....... Jacob Wishnia R.Ph.
Amneal makes new executive appointments
BRIDGEWATER, N.J. — Generic drug maker Amneal Pharmaceuticals has added four new executives, the company said.
Joseph Todisco has been appointed SVP global corporate strategy and business development. Previously serving as VP business development for Ranbaxy, Todisco will be responsible for the growth of Amneal’s U.S. generics business and development of partnerships, mergers and acquisitions.
Narasimhan Mani has been appointed director of global business development and portfolio, and will head the identification and execution of international opportunities and alliances, research and development product management and selection, and corporate portfolio management. Before working for Amneal, Mani was business development manager for Johnson & Johnson.
Pranav Mehta has been appointed global director of purchasing, overseeing research and development procurement, commercial active pharmaceutical ingredients and packaging. Mehta previously worked for JPMorgan Chase & Co.
Hanumantha Rao has been appointed director of business development and will seek alliances in Europe, Asia, Africa and the Middle East. Before working for Amneal, Rao was assistant director of strategic sourcing and business development for North America and Europe at Dr. Reddy’s Labs.
No comments found
FTC approves Valeant’s acquisitions of Dermik, Ortho Dermatologics
MISSISSAUGA, Ontario — The Federal Trade Commission has voted to approve Valeant’s acquisitions of Dermik, a unit of French drug maker Sanofi that makes drugs for skin conditions, and Ortho Dermatologics, a division of Johnson & Johnson that also makes skin drugs.
At the same time, the FTC is requiring Valeant to dissolve its collaboration with Spear Pharmaceuticals related to the wrinkle and pigmentation disorder drug Refissa (tretinoin) and generic emollient cream, and divest its generic version of Sanofi’s acne drug BenzaClin (clindamycin and benzoyl peroxide gel) and its authorized generic version of its own actinic and solar keratosis drug, Efudex (fluorouracil cream).
The company said it expected to complete its acquisition of Ortho Dermatologics on Monday and of Dermik by the end of the year.
No comments found